Small Molecule Strategy Degrades Many Disease Proteins at Once in Cell Models

A new study reports a strategy called simulated protein degradation (SPD), which uses small molecule agonists to activate stress-responsive E3 ligases, enabling the simultaneous degradation of multiple disease-causing proteins. The work, published in Science, addresses a key limitation of existing targeted protein degradation (TPD) approaches, which typically eliminate only one protein at a time.

TPD is an emerging therapeutic strategy that removes disease-causing proteins rather than simply blocking their activity. By degrading rather than inhibiting proteins, TPD can produce more sustained effects and disable protein functions linked to the development of drug resistance, offering potential advantages in treating cancer, autoimmune disease, and inflammatory syndromes. However, because current TPD approaches target individual proteins, their applicability to complex neurodegenerative and mitochondrial diseases, which often involve dysregulation of several proteins, has been limited.

Previous research had identified E3 ligases that respond to cellular stress by recognizing and degrading multiple defective proteins that accumulate in degenerative diseases. Leveraging these observations, Srividya Chandrasekhar and colleagues developed SPD as a way to harness this natural cleanup machinery with drug-like molecules.

Using a differential screening approach, the researchers identified the reductive stress response E3 ligase CUL2FEM1B. This ligase protects mitochondrial function by removing proteins that obstruct mitochondrial import, the process by which proteins are delivered into mitochondria to keep these energy-producing organelles working properly.

In experiments reported in the study, activating CUL2FEM1B improved mitochondrial protein import and energy production. The activation restored cellular function and neuronal survival in models of mitochondrial and neurodegenerative disorders, including Friedreich’s ataxia. These are preclinical cell and disease models, so the findings represent early-stage evidence rather than demonstrated clinical benefit in patients.

According to the authors, the approach demonstrated high potency and specificity without causing oxidative stress or mitochondrial damage, an important consideration for any therapy that deliberately manipulates protein destruction pathways inside cells.

Beyond its potential as a standalone therapy, the researchers note that SPD could also complement existing TPD therapies. By improving treatment specificity, SPD might enable the combined removal of both natural protein targets and disease-associated proteins, offering what the authors describe as a promising new direction for treating complex diseases.

In a related Perspective published alongside the study, Ramanujan Hegde discusses the research and its findings in greater detail, situating the work within the broader effort to expand protein degradation technologies beyond single-protein targets.

If the approach can be translated beyond laboratory models, it could broaden the therapeutic reach of targeted degradation to conditions involving multiple dysfunctional proteins, a category that includes many neurodegenerative and mitochondrial disorders for which current treatment options remain limited. Further development and testing would be needed before any clinical application.

Subject of Research: Simulated protein degradation using small molecule agonists to activate the E3 ligase CUL2FEM1B for removing multiple disease-causing proteins

Article Title: Stimulating protein degradation to treat neurodegenerative disease

Article References: Stimulating protein degradation to treat neurodegenerative disease. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: targeted protein degradation, simulated protein degradation, E3 ligase, CUL2FEM1B, mitochondria, neurodegenerative disease, Friedreich's ataxia, mitochondrial protein import, small molecule agonists, Science, drug resistance, cellular stress